NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 84 resultados LastUpdate Última actualización 22/09/2020 [14:43:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS

NºPublicación: WO2020185695A1 17/09/2020

Solicitante:

UNIV OREGON STATE [US]
BEAUDRY CHRISTOPHER M [US]
JU XUAN [US]

Resumen de: WO2020185695A1

Disclosed herein are embodiments of a compound having a Formula I, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereoAlso disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

traducir

COMPOSITION AND METHOD FOR TREATING PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA

NºPublicación: US2020289520A1 17/09/2020

Solicitante:

RHIZEN PHARMACEUTICALS SA [CH]

KR_20200096781_A

Resumen de: US2020289520A1

The present invention relates to the use of a dual selective PI3K delta and gamma protein kinase inhibitor, such as (S)-2-(1-((9H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (Compound (A), also known as tenalisib) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing such an inhibitor for the treatment of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). 34 139095.00100/115268675v.1

traducir

USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT

NºPublicación: US2020291486A1 17/09/2020

Solicitante:

BIOVENTURES LLC [US]

US_2017342501_A1

Resumen de: US2020291486A1

Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.

traducir

Ligands to GM-CSF or GM-CSF-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-HCT

NºPublicación: AU2019224550A1 17/09/2020

Solicitante:

UNIV ZUERICH [CH]

US_2019256587_A1

Resumen de: AU2019224550A1

Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.

traducir

MACROCYCLIC COMPOUNDS

NºPublicación: WO2020185606A1 17/09/2020

Solicitante:

ZENO MAN INC [US]

Resumen de: WO2020185606A1

Disclosed are macrocyclic compounds of formula (I) comprising a 2-carboxy indole ring. Such compounds, and their pharmaceutically acceptable salts, are useful as Mcl-1 (myeloid cell leukemia-1) inhibitors. The compounds may be used in treating a disease or condition, such as cancer.

traducir

FELINE CALICIVIRUS VACCINE

NºPublicación: EP3706788A1 16/09/2020

Solicitante:

INTERVET INT BV [NL]

Resumen de: CA3080430A1

The present invention provides new feline calicivirus vaccines, including multivalent vaccines. The present invention also provides methods of making and using the vaccines.

traducir

TREATMENT OF CNS LYMPHOMA AND SYSTEMIC LYMPHOMA WITH INTRACEREBROVENTRICULARLY ADMINISTERED CD19 CAR

NºPublicación: EP3707246A1 16/09/2020

Solicitante:

HOPE CITY [US]
WANG XIULI [US]
FORMAN STEPHEN J [US]

WO_2019094498_A1

Resumen de: WO2019094498A1

An improved method of treating cancers CD19 CAR T cells by administering the CD19 CAR T cells to the central nervous system, e.g., by intracerebroventricular administration, is described.

traducir

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)

NºPublicación: EP3708185A2 16/09/2020

Solicitante:

IMMATICS BIOTECHNOLOGIES GMBH [DE]

TW_201930347_A

Resumen de: EP3708185A2

Provided are peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. Provided are also tumor-associated cytotoxic T cell (CTL) peptide epitopes that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. Provided are several peptide sequences derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

traducir

ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD

NºPublicación: WO2020179646A1 10/09/2020

Solicitante:

UNIV SAGA [JP]
OHARA PHARMACEUTICAL CO LTD [JP]

Resumen de: WO2020179646A1

An adult T-cell leukemia-lymphoma (ATL) detection method is provided which involves determining the presence or absence in a target biological sample of DNA methylation of at least one gene selected from the group consisting of SERPINB6, NELL2, THEMIS, ZSCAN18, LAIR1, CD7, RNF130, ZIK1, LYPD3, TMEM45B, POMC, FHIT, MDS2, HOOK1, SORCS3, C2orf40, ZNF662, SPG20, ZNF717, LZTFL1, KLHL34 and BCL9, wherein DNA methylation of at least one of the aforementioned genes indicates that the subject has developed or is at risk of developing ATL. By this means, a new detection method of adult T cell leukemia-lymphoma (ATL) is provided.

traducir

METHOD OF DISCRIMINATING BETWEEN INFLAMMATORY BOWEL DISEASE AND GASTROINTESTINAL LYMPHOMA, DISCRIMINATION MARKER AND KIT

NºPublicación: WO2020179887A1 10/09/2020

Solicitante:

UNIV TOKYO [JP]

JP_2020143951_A

Resumen de: WO2020179887A1

The purpose of the present invention is to provide a method for discriminating between inflammatory bowel disease (IBD) and small-cell gastrointestinal lymphoma in carnivorous animals. A method for discriminating between IBD and small-cell gastrointestinal lymphoma in carnivorous animals is provided which involves a step for measuring the expression level in a test animal of an antimicrobial peptide selected from the group consisting of bactericidal/permeability-increasing protein (BPI), lactoferrin, secretory leukocyte peptidase inhibitor (SLPI), lysozyme and canine β-defensin.

traducir

TETRAMERIC PROTEIN SCAFFOLDS AS NANO-CARRIERS OF THERAPEUTIC PEPTIDES FOR TREATING CANCER AND OTHER DISEASES

NºPublicación: WO2020181197A1 10/09/2020

Solicitante:

UNIV MARYLAND [US]
LU WUYUAN [US]
MA BOHAN [CN]

Resumen de: WO2020181197A1

A protein-based peptide drug carrier derived from the tetramerization domain of the chimeric oncogenic protein Bcr/Abl of chronic myeloid leukemia. Peptides to be delivered are grafted to the N-terminal helical region of Bcr/Abl tetramer. To facilitate cellular uptake, an Arg-repeating hexapeptide is added to the C-terminal end of the Bcr/Abl protein. The protein-based delivery strategy provides a clinically viable solution to p53-inspired anticancer therapy and is applicable to the development of many other peptide therapeutics to target other intracellular protein-protein interactions responsible for disease initiation and progression.

traducir

SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE

NºPublicación: WO2020181207A1 10/09/2020

Solicitante:

UNIV MICHIGAN REGENTS [US]

Resumen de: WO2020181207A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to small molecule compounds having bicyclic and tetracyclic quinone scaffolds which have antiproliferative activities through, for example, induction of reactive oxygen species. The invention further processes for preparing, and methods for using these compounds to treat cancer (e.g., pancreatic cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer).

traducir

CAR-T CELLS WITH HUMANIZED CD19 SCFV

NºPublicación: WO2020180551A1 10/09/2020

Solicitante:

PROMAB BIOTECHNOLOGIES INC [US]
FOREVERTEK BIOTECHNOLOGY CO LTD [CN]

Resumen de: WO2020180551A1

The present invention is directed to a humanized CD19 single-chain variable fragment (scFv), comprising the amino acid sequence of SEQ ID NO: 8. The present invention is also directed to a CD19 chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The humanized anti-CD19 scFv of the present invention exhibits selective and high-affinity binding to CD19. CD19-CAR T cells based on humanized scFv of the present invention are useful to treat patients with B-cell malignancies including leukemia and lymphomas.

traducir

TREATMENTS AND DIAGNOSTICS FOR CANCERS

NºPublicación: US2020281946A1 10/09/2020

Solicitante:

UNIV WAYNE STATE [US]

US_2018280412_A1

Resumen de: US2020281946A1

Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).

traducir

TELOMERE-CONTROLLING GENE FAMILY DISCOVERED IN MOUSE THYMUS LYMPHOMA CELL IRRADIATED WITH LOW-DOSE RATE LOW-LEVEL RADIATION, AND METHOD FOR DETECTING SAME

NºPublicación: US2020283836A1 10/09/2020

Solicitante:

KOREA HYDRO & NUCLEAR POWER CO [KR]

CN_111148848_A

Resumen de: US2020283836A1

The present invention relates to a method of detecting a telomere-controlling gene family that responds to low-dose-rate low-level radiation, and more particularly to a method of detecting a telomere-controlling gene that is expressed in common or alone by applying low-dose low-level radiation to mouse thymic lymphoma cells and then measuring the expression levels of telomere-controlling genes. By providing the method of detecting the telomere-controlling gene family that responds to low-dose-rate low-level radiation according to the present invention, telomere-controlling genes can be used as low-level-radiation telomere-controlling genes with which the relationship between radiation exposure and carcinogenesis of industrial and medical workers can be evaluated, as low-level-radiation telomere-controlling genes with which cancer progression and the extent of treatment of cancer patients can be evaluated, and also as a low-level telomere-controlling gene recovery indicator with which the causal relationship between radiation and carcinogenesis can be evaluated.

traducir

ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA

NºPublicación: US2020283542A1 10/09/2020

Solicitante:

GENMAB AS [DK]

JP_2020141689_A

Resumen de: US2020283542A1

Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

traducir

ANTIBODY

NºPublicación: US2020283533A1 10/09/2020

Solicitante:

UNIV OSAKA [JP]

JP_2019201641_A

Resumen de: US2020283533A1

Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

traducir

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

NºPublicación: US2020283397A1 10/09/2020

Solicitante:

IMAGO BIOSCIENCES INC [US]

US_2018312474_A1

Resumen de: US2020283397A1

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

traducir

AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA

NºPublicación: US2020283417A1 10/09/2020

Solicitante:

UNIV MARYLAND [US]

CA_3039191_A1

Resumen de: US2020283417A1

The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

traducir

Compositions and methods for treating hematologic cancers targeting the SIRPalpha - CD47 interaction

NºPublicación: AU2020220183A1 10/09/2020

Solicitante:

HOSPITAL FOR SICK CHILDREN [CA]
UNIV HEALTH NETWORK [CA]

AU_2018256470_A1

Resumen de: AU2020220183A1

The invention relates to modulating the SIRPa - CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided 5 methods and uses of SIRPa polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

traducir

Combination therapy using belinostat and pralatrexate to treat lymphoma

NºPublicación: AU2020220197A1 10/09/2020

Solicitante:

SPECTRUM PHARMACEUTICALS INC [US]

Resumen de: AU2020220197A1

The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.

traducir

Methods for treating acute myeloid leukemia and related conditions

NºPublicación: AU2019230013A1 10/09/2020

Solicitante:

GLYCOMIMETICS INC [US]

WO_2019173229_PA

Resumen de: AU2019230013A1

Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I) a prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.

traducir

Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies

NºPublicación: AU2019218271A1 10/09/2020

Solicitante:

FORTY SEVEN INC [US]

US_2019248915_A1

Resumen de: AU2019218271A1

Disclosed is a regimen to treat a CD20+ cancer, in particular a lymphoma. The regimen involves several cycles of administration of anti-CD20 and anti-CD47 antibodies at appropriate dosage and administration intervals.

traducir

METHODS OF DETECTING AND TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA

NºPublicación: WO2020181219A1 10/09/2020

Solicitante:

UNIV COLORADO REGENTS [US]

Resumen de: WO2020181219A1

The present disclosure relates to methods of identifying AML patients who will be resistant to venetoclax therapy and methods of treating venetoclax-resistant patients with myeloid leukemia cell differentiation protein (MCL-1) inhibitors.

traducir

METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS

Nº publicación: WO2020180663A1 10/09/2020

Solicitante:

KURA ONCOLOGY INC [US]

Resumen de: WO2020180663A1

The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma ("PTCL"), lymphoma is angioimmunoblastic T-cell lymphoma (AITL), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.

traducir

Página1 de 4 nextPage por página

punteroimgVolver